"name","description","uuid:ID","rationale","id","instanceType","label"
"Study Design 1","The main design for the study","3627ad85-2c9b-4a18-a30a-4a83fb2dd9b4","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","StudyDesign",""
